DaVita HealthCare Partners (DVA) saw its stock plummet by 5.05% during intraday trading on Thursday, as several prominent analysts lowered their price targets for the company. The healthcare provider faced downward pressure following a series of analyst reports that expressed concerns about the company's near-term prospects.

Barclays led the bearish sentiment by reducing its price target for DaVita from $149 to $143, while maintaining an Equal-Weight rating on the stock. Deutsche Bank took an even more cautious stance, cutting its target price more significantly from $137 to $126. These downward revisions suggest that analysts are adjusting their expectations for DaVita's future performance.

Despite the stock's sharp decline, the overall analyst consensus remains cautious. According to data from FactSet, DaVita currently has an average rating of "hold" with a mean price target of $147. This indicates that while analysts see potential upside from current levels, they also recognize challenges that could impact the company's growth. Investors will likely be closely watching DaVita's upcoming financial results and management commentary for further insights into the factors driving these analyst revisions.